[Growth, immunophenotype and interleukin-6 level of bone marrow stromal cells in patients with multiple myeloma and acute leukemia].
The aim of this study was to investigate the growth, immunophenotype and interleukin-6 (IL-6) level of bone marrow stromal cells (BMSC) in patients with acute leukemia (AL) and multiple myeloma (MM). BMSC was cultured by wall-adhesion method and the growth of BMSC was observed. The immunophenotype and cell cycle of BMSC were detected by flow cytometry. The level of interleukin 6 (IL-6) in BMSC culture system was detected by ELISA. The results showed that the primary (17.3 +/- 7.8 days) and continuous (10.3 +/- 3.5 days) growth cycle of BMSC in patients with AL were significantly shorter than those in patients with MM (26.5 +/- 6.3 and 16.5 +/- 4.1 days respectively), and shorter than those in normal controls (25.8 +/- 6.3 and 17.5 +/- 2.4 days) respectively. Similarly, S + G2% (17.4 +/- 3.6%) of BMSC in patients with AL was significantly higher than those in patients with MM (8.5 +/- 2.2%) and in normal controls (8.9 +/- 2.3%). All of the three groups showed positive antigen expressions with CD29 and CD44 were 100%, while CD138, CD34, CD54, CD56 positive were not expressed and CD106 was partially expressed positive. The supernatant IL-6 level of BMSC system in MM patients (1288.5 +/- 736.7 pg/ml) was significantly higher than those in AL patients (859.3 +/- 203.1 pg/ml) and normal controls (850.9 +/- 129.5 pg/ml). It is concluded that the growth, S + G2% of cell cycle and IL-6 level of BMSC in patients with MM, AL and normal control are significantly different, whereas the antigen expressions are similar.
Zhuang
Jun-Ling
JL
Department of Hematology, Peking Union Hospital, Beijing 100730, China. em-myzhuang@sina.com
Wang
Xuan
X
Zhang
Jie-Ping
JP
Wu
Yong-Ji
YJ
D000208:Acute Disease; D001854:Bone Marrow Cells / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D049109:Cell Proliferation; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis; D016130:Immunophenotyping; D019012:Integrin beta1 / Q000032:analysis; D015850:Interleukin-6 / Q000032:analysis; D007938:Leukemia / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D009101:Multiple Myeloma / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D017154:Stromal Cells / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D014407:Tumor Cells, Cultured
D018960:Hyaluronan Receptors; D019012:Integrin beta1; D015850:Interleukin-6